<DOC>
	<DOCNO>NCT01204905</DOCNO>
	<brief_summary>This pilot , open-label study raltegravir maraviroc combination treatment antiretroviral naïve patient . The study enroll 10 antiretroviral naïve patient CD4 count ≥ 350 viral load &gt; 5,000 . The subject follow 48 week . The combination two agent potential potent regimen minimal metabolic complication . However , studied combination previously . This pilot study propose evaluate combination antiretroviral naïve patient document safety efficacy combination order provide clinician treatment regimen minimize risk metabolic complication .</brief_summary>
	<brief_title>R5 Integrase Study HIV-1 Naive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV1 infection CD4 count ≥ 350 RNA &gt; 5,000 CCR5 tropic virus Baseline genotype without significant mutation know confer antiretroviral drug resistance currently license antiretroviral agent Antiretroviral naïve ( &lt; 7 day experience ) 1875 year age Subject able provide inform consent study Women childbearing age agree remain abstinent use ( partner use ) acceptable method birth control throughout study . Acceptable method birth control define intrauterine device ( IUD ) , diaphragm spermicide , contraceptive sponge , condom , vasectomy . Dual/mixed tropic virus , Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal ; Total bilirubin &gt; 1.5 mg/dL , Women pregnant breastfeeding , History malignancy Enrollment experimental protocol concomitant use drug know impact impact term pk drugdrug interaction either raltegravir maraviroc . This include inducer UGT1A1 ( rifampin , phenytoin , Phenobarbital rifabutin , St. John 's wart ) well CYP3A inhibitor ( ketoconazole , itraconazole , clarithromycin , nefazodone telithromycin ) CYP3A inducer ( rifampin , carbamazepine , Phenobarbital phenytoin ) Enrollment experimental protocol receive investigational agent ( antiretroviral nonantiretroviral ) within 30 day study enrollment Chronic active hepatitis B infection Subject history current evidence condition , therapy , laboratory abnormality circumstance might confound result study , interfere patient 's participation full duration study , best interest patient participate . Subject unlikely adhere study procedure , keep appointment , plan relocate study . Subject require anticipated require prohibit medication note protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>CD4</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Human Immunodeficiency Virus ( HIV )</keyword>
</DOC>